Difficulty: Medium
Average Score: 93%
Practice
A preterm neonate is being treated for respiratory distress syndrome. Which of the following is the primary benefit of surfactant therapy?
Correct answer
B
Rationale
In the context of nursing interventions for pediatric respiratory distress, the primary benefit of surfactant therapy in treating respiratory distress syndrome in preterm neonates is reducing surface tension in the alveoli, which is option B.
Surfactant is a substance naturally produced in the lungs that helps reduce surface tension in the alveoli, preventing their collapse during exhalation and promoting lung compliance. In preterm neonates with respiratory distress syndrome, there is a deficiency of surfactant, leading to alveolar collapse and difficulty in breathing. By administering exogenous surfactant, healthcare providers can improve lung function by reducing surface tension, thereby preventing atelectasis and improving gas exchange.
Option A, promoting lung growth, is not the primary benefit of surfactant therapy. While surfactant does support lung development by preventing alveolar collapse and promoting expansion, its primary function in this context is to reduce surface tension.
Option C, improving oxygen uptake in the placenta, is incorrect as surfactant therapy directly impacts lung function and alveolar stability, not oxygen uptake in the placenta.
Option D, decreasing blood pressure in the lungs, is also incorrect. Surfactant therapy primarily focuses on improving lung function and oxygenation by reducing surface tension in the alveoli, rather than directly affecting blood pressure in the lungs.
Understanding the primary benefits and mechanisms of surfactant therapy in treating respiratory distress syndrome is crucial for nursing interventions in pediatric patients, especially preterm neonates, to provide effective and evidence-based care to improve respiratory outcomes.
Surfactant is a substance naturally produced in the lungs that helps reduce surface tension in the alveoli, preventing their collapse during exhalation and promoting lung compliance. In preterm neonates with respiratory distress syndrome, there is a deficiency of surfactant, leading to alveolar collapse and difficulty in breathing. By administering exogenous surfactant, healthcare providers can improve lung function by reducing surface tension, thereby preventing atelectasis and improving gas exchange.
Option A, promoting lung growth, is not the primary benefit of surfactant therapy. While surfactant does support lung development by preventing alveolar collapse and promoting expansion, its primary function in this context is to reduce surface tension.
Option C, improving oxygen uptake in the placenta, is incorrect as surfactant therapy directly impacts lung function and alveolar stability, not oxygen uptake in the placenta.
Option D, decreasing blood pressure in the lungs, is also incorrect. Surfactant therapy primarily focuses on improving lung function and oxygenation by reducing surface tension in the alveoli, rather than directly affecting blood pressure in the lungs.
Understanding the primary benefits and mechanisms of surfactant therapy in treating respiratory distress syndrome is crucial for nursing interventions in pediatric patients, especially preterm neonates, to provide effective and evidence-based care to improve respiratory outcomes.